Mallinckrodt, Inc.

Mallinckrodt Medical, Inc.

Medibeacon Inc.

Other

Liebel-flarsheim Company LLC

Guerbet

Biosynthema Inc.

Medibeacon Development LLC

Mallinkrodt Inc.

Mallinkcrodt, Inc.

Raghavan Rajagopalan

Richard Bradley Dorshow

Samuel I Achilefu

Joseph E Bugaj

William L Neumann

Muthunadar P Periasamy

Dennis A Moore

Gary Lee Cantrell

Ananthachari Srinivasan

Leon R Lyle

Scott T Depierro

Ella Y Fung

Bob O Basore

Hermo N Jimenez

Steven R Woulfe

Rebecca A Wallace

Amolkumar Karwa

Thomas Edward Rogers

Martin Paul Debreczeny

Dennis L Nosco

Karen F Deutsch

John Nicholas Freskos

David H White

David W Berberich

William P Cacheris

Donald R VanDeripe

Thomas J Dunn

Amruta Reddy Poreddy

T Jeffrey Dunn

Arthur H Combs

Max D Adams

Lynn A deLearie

Jean-Luc Vanderheyden

Frederick G Jacobs

Joseph B Bugaj

Richard D Dorshow

Joseph E Bugai

Samuel Achilefu

Joseph Edward Bugaj

The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The system includes a computing device, a power supply, one or more sensors, and at least one tracer agent that fluoresces when exposed to electromagnetic radiation. The electromagnetic radiation is detected using the sensors, and the rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.

Compositions and systems for renal function determination

The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The method includes administering a pyrazine compound of Formula I to a patient and monitoring the rate in which the kidneys of the patient eliminate the pyrazine from the systemic circulation of the patient. The pyrazine compound fluoresces when exposed to electromagnetic radiation which is detected using one or more sensors. The rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.

Methods for renal function determination

In certain aspects, the invention relates to processes for using renally excretable optical agents to detect one or more tissues of the renal system of a surgical patient. In certain aspects, the invention relates to a kit including a biocompatible composition containing one or more optical agents and instructions for using the optical agent(s) in a process of the present invention.

Methods of using optical agents

Process for using optical agents

The present invention provides tissue sealant compositions and vasculature closure devices useful for the optical detection of tissue seal and/or clot formation. Compositions and devices of the present invention comprise optical dyes which undergo an observable change as the compositions and/or devices are incorporated into a tissue seal and/or clot, for example a change in fluorescence quantum yield and/or a change in visual color including a change in emission and/or absorption wavelength. Tissue sealants and vasculature closure devices of the present invention are useful for visualizing seal and/or clot formation, for example, during or after surgical procedures, after catheter removal, etc. The present invention further provides methods for formation and optical detection of tissue seals or vasculature puncture closures as well as medical kits useful for the formation and optical detection of tissue seals or vasculature puncture closures.

Tissue sealant compositions, vascular closure devices, and uses thereof

The present invention relates to pyrazine derivatives such as those represented by Formulas I and II. Xto Xof Formulas I and II may be characterized as electron withdrawing groups, while Yto Yof Formulas I and II may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing organ (e.g., kidney) function. In a particular example, an effective amount of a pyrazine derivative that is capable of being renally cleared may be administered into a patient's body. The pyrazine derivative may capable of one or both absorbing and emanating spectral energy of at least about 400 nm (e.g., visible and/or infrared light). At least some of the derivative that is in the body may be exposed to spectral energy and, in turn, spectral energy may emanate from the derivative. This emanating spectral energy may be detected and utilized to determine renal function of the patient. 

Fluorescent pyrazine derivatives and methods of using the same in assessing renal function

The present invention relates to pyrazine derivatives capable of absorbing and emanating spectral energy in the visible and/or near infrared spectrum. Pyrazine derivatives of the invention may be administered to a patient in the form of a pharmaceutically acceptable composition and utilized in medical (e.g., diagnostic imaging) procedures.

Pyrazine derivatives with extended conjugation and methods of using the same in optical applications

The present invention relates to pyrazine derivatives such as those represented by Formulas I and II below. Xto Xof the compounds of Formulas I and II may be characterized as electron withdrawing groups. In contrast, Yto Yof the compounds of Formulas I and II may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing renal function. In particular, an effective amount of a pyrazine derivative of the invention may be administered into a body of a patient. The pyrazine derivative that is in the body may be exposed to visible and/or infrared light to cause spectral energy to emanate from the pyrazine derivative. This emanating spectral energy may be detected and utilized to determine renal function of the patient.

Pyrazine derivatives and uses thereof in renal monitoring

This invention is directed to non-benzenoid aromatic compounds. Other aspects include methods of using non-benzenoid aromatic compounds for imaging and phototherapeutic uses thereof. Non-benzenoid compounds provided herein generally have one or more substituent groups which allow tailoring of the spectral properties or provide photoreactivity or targeting ability.

Non-benzenoid aromatic systems for imaging, monitoring and therapy

The present disclosure relates generally to a process for the synthesis of 1,4,7,10-tetraazacyclododecane ligands, chelates, and derivatives thereof. In particular, the present disclosure is directed to a process for the synthesis of 1,4,7,10-tetraaza-1,4,7,10-tetrakis(carboxymethyl)cyclododecane (DOTA) ligands, corresponding DOTA-metal chelates, and various derivatives thereof.

Process for the preparation of macrocyclic polyazacarboxylate ligands and chelates

Growing community of inventors

Solon, OH, United States of America

Raghavan Rajagopalan